Madrigal Pharmaceuticals, Inc. · NASDAQ:MDGL
Madrigal Pharmaceuticals — Merger or Acquisition (April 2016)
21 slides from Madrigal Pharmaceuticals's merger presentation, Apr 14, 2016
Slide 1: Synta Pharmaceuticals and Madrigal Pharmaceuticals Merger Agreement
Synta Pharmaceuticals and Madrigal Pharmaceuticals Merger Agreement NASDAQ: SNTA | April 14, 2016 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements Any statements made in this press release relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including without limitation, whether and when our recently announced merger with M
Slide 3: Additional Information about the Merger and Where to Find It
Additional Information about the Merger and Where to Find It This presentation does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. A definitive proxy statement and a proxy card will be filed with the SEC and will be ma
Slide 4: Synta-Madrigal Terms
Synta-Madrigal Terms • All-stock transaction: Synta to acquire all outstanding shares of Madrigal in exchange for approximately 253.9 million newly issued shares of Synta common stock • Upon completion of the proposed acquisition, existing Synta shareholders will own 36.0% of the combined company an
Slide 5: Synta-Madrigal Merger Agreement
Synta-Madrigal Merger Agreement • Follows Synta’s extensive review of strategic alternatives • Combined company will be focused on the development of novel small-molecule drugs addressing major unmet needs in cardiovascular-metabolic diseases and NASH • Lead compound, MGL-3196, is a first-in-class,
Slide 6: Synta-Madrigal Leadership
Synta-Madrigal Leadership • Combined company will be led by an experienced management team with multiple successful NDA/EMAs and marketed products – Paul Friedman, M.D. - Chairman and CEO • Former CEO of Incyte Pharmaceuticals; former President of DuPont Pharmaceuticals Research – Rebecca Taub, M.D.
Slide 7: Paul A. Friedman, M.D.
ZSYNTA PHARMACEUTICALS® Dy Paul A. Friedman, M.D. Madrigal Pharmaceuticals
Slide 8: Building a Platform in Lipid and Liver Disorders with MGL-3196
Building a Platform in Lipid and Liver Disorders with MGL- 3196, a First-in-Class Thyroid Hormone-β (THR-β) Agonist Lead compound, MGL-3196, a Phase 2-ready liver-directed thyroid hormone receptor-β First-in-Class (THR-β) agonist Approach • Once-daily oral dosing • Favorable safety and efficacy prof
Slide 9: Rebecca Taub, M.D.
ZSYNTA PHARMACEUTICALS® Dy Rebecca Taub, M.D. Madrigal Pharmaceuticals
Slide 10: MGL-3196, a First-in-Class Liver-Directed THR-β Agonist
MGL-3196, a First-in-Class Liver-Directed THR- β Agonist • We believe MGL-3196 is the first bona fide THR-β selective molecule – Discovery of MGL-3196 and backups at Roche utilized a novel functional assay that went beyond what previous companies had done (simple receptor binding assay) – Earlier co
Slide 11: Madrigal Pipeline
Madrigal Pipeline Compound/Target Disease State Pre-Clinical Phase 1 Phase 2 Phase 3 MGL-3196 NASH Thyroid Hormone Receptor-β (THR-β) Agonist FH MGL-3745 Thyroid Hormone – (Same as 3196) Receptor-β (THR-β) Agonist (Backup) • Thyroid analogue platform (MGL-3196, backup, new molecules) • Biliary disor
Slide 12: Differentiated NASH Opportunity
Differentiated NASH Opportunity Large & • WW NASH market estimated at $35bn-$40bn Growing • While epidemiology data varies, ~2-3% of the US population is thought to have NASH, and expected to grow given the high rate of growth of obesity and diabetes Unserved • No FDA approved treatment options Mark
Slide 13: THR-β Benefits Across the Spectrum of Early to Advanced NASH
THR-β Benefits Across the Spectrum of Early to Advanced NASH Evidence from human and animal data from Madrigal and multiple published studies NASH Normal Liver Fatty Liver Cirrhosis inflammation and fibrosis METABOLIC BENEFITS ANTI-INFLAMMATORY REDUCED NASH Effects of MGL-3196: liver fat & lipotoxi
Slide 14: MGL-3196: Marked and Rapid Improvement in Liver Health
MGL-3196: Marked and Rapid Improvement in Liver Health Upper panels: 24d study in 17 wk old DIO mice (po, qd) on high fat diet (HFD) 13 wks; lower panels: 24d study in 40 wk old DIO mice on HFD 35 wks Liver Size Liver Triglycerides 5 70 Insulin Tolerance Test Liver % Body Weight 120 Triglycerides mg
Slide 15: MGL-3196: Reduction of Key NASH, Fibrosis Pathway Genes
MGL-3196: Reduction of Key NASH, Fibrosis Pathway Genes at Human Comparable Drug Levels 25 week study in DIO, lean control mice and HFD mice treated with 0.1 to 3 mg/kg MGL-3196 or Rosiglitazone (3mg/kg) MGL-3196 (mg/kg) HFD mouse model Inflammation HFD Lean 0.1 0.3 1 3 Rosi MCP-1/CCL2 • Up-regulati
Slide 16: MGL-3196: Robust LDL and Triglyceride Lowering in Multiple Dose Phase 1 Study
MGL-3196: Robust LDL and Triglyceride Lowering in 14 Day Multiple Dose Phase 1 Study Change in Lipids After 14 Days 20 10 %Change From Baseline MGL-3196, 0 Placebo Subtracted Chol LDL-C ApoB Non-HDL-C TG -10 * * * -20 ** ** *** ** *** ** ** ** *** *** -30 *** *** *** -40 -50 “ *** p<0.001 ** p<0.01
Slide 17: Strong Positioning in NASH Landscape
Strong Positioning in NASH Landscape NAS Fibrosis Liver NASH Insulin CV Compound Phase LDL TGs Side Effects Score Score Lipids Prevention Sensitivity Risk CV Well- MGL-3196 1 ✔ ✓ ✔ ✔ ✔ Benefit tolerated ✔Benefit ✓Small benefit Decrease Green = Good • Pleiotropic and cardio-beneficial actions po
Slide 18: Unmet Needs in FH, a Severe Genetic Dyslipidemia
Unmet Needs in FH, a Severe Genetic Dyslipidemia • HeFH and HoFH caused primarily by inactivating mutations in LDL Severe Debilitating receptor Dyslipidemia • Early onset cardiovascular disease, HoFH < age 20 Prevalence • 1/200-1/500 HeFH; 1/250,000-1/1,000,000 HoFH • Higher frequency in certain gen
Slide 19: MGL-3196: Unique and Complementary Lipid Lowering Profile
MGL-3196: Unique and Complementary Lipid Lowering Profile Cholesterol Breakdown Elimination MGL-3196 both LDL receptor dependent and independent ApoB cholesterol lowering Lp(a) • Thyroid pathway clinically validated and differentiated in FH – MGL-3196 lowers LDL in concert with statins in clinical,
Slide 20: Potential Near and Long-term Value Drivers
Potential Near and Long-term Value Drivers Data on NASH topline 3 mo data Completion of MGL-3196 NASH Ph2 long-term 1oEndpoint Data on Liver Fat NASH Ph2 NASH topline 6 mo toxicology NASH Ph2 Biomarkers Liver Biopsy studies 2015 2016 2017 2018 MGL-3196 HeFH Ph 2 Data on Start of dosed with HoFH Ph2a
Slide 21: Thank you
Thank you NASDAQ: SNTA | April 14, 2016 21
Madrigal Pharmaceuticals — Merger or Acquisition (April 2016) on 6ix